Press Release, April 16, 2009                                                  

           
Diamyd Medical is conducting two clinical Phase III trials of
the Diamyd®       
diabetes vaccine in children and adolescents with recent
onset type 1 diabetes: 
one in the US and one in nine European countries. In
parallel the company is    
discussing with the regulatory agencies about
combining the two trials into one 
global trial.                              
                                    

In addition to reducing costs,
combining the trials would mean that countries   
with the fastest rate of
patient recruitment could contribute to the greatest   
extent. The Phase III
program encompasses ten countries: Italy, Finland, France,
the Netherlands,
Slovenia, Spain, the UK, Sweden, Germany and the US. The plan  
is for the
global trial to serve as the basis for market approval in both Europe
and the
US. Diamyd Medical's continued intention is to report Phase III data   

during the fourth quarter of 2010.                                           
  

Patient recruitment is growing sharply at present, as more clinics are
being    
added. There are currently 74 active recruiting clinics in the US
and Europe, 34
of which have joined since the beginning of the year.          
                

“We estimate that the expanded number of clinics will
enable us to screen 100   
children and adolescents in April,” says Elisabeth
Lindner, President and CEO of
Diamyd Medical.                                 
                               

For additional information, please contact: 
                                   
Elisabeth Lindner, President and CEO
Diamyd Medical AB (publ.)                  
Tel: +46  (0)8 6610026            
                                             

For pictures and press
material, please contact:                                
Alexandra Fleetwood,
Director Communications Diamyd Medical AB (publ.),        

alexandra.fleetwood@diamyd.com                                               
  
Tel: +46 (0)8 661 0026                                                     
    

About Diamyd Medical                                                   
        
Diamyd Medical is a Swedish biopharmaceutical company focusing on the
          
development of pharmaceuticals for the treatment of autoimmune
diabetes and its 
complications. The company's most advanced project is the
GAD-based drug Diamyd®
for type 1 diabetes. Phase III trials for this drug are
in progress in both the 
US and Europe. In addition, the Company has initiated
clinical studies in the US
in the area of chronic pain, using its Nerve
Targeting Drug Delivery System. The
Company has also out-licensed the use of
GAD for the treatment of Parkinson's   
disease.                              
                                         

Diamyd Medical has offices in
Sweden and in the US. Shares are listed on the OMX
Stockholm Nordic Exchange
(ticker: DIAM B) and on OTCQX in the US (ticker:      
DMYDY) administered by
the Pink Sheets and the Bank of New York (PAL). Further  
information is
available on the company's website; www.diamyd.com.              

This
information is disclosed in accordance with the Swedish Securities Markets

Act, the Swedish Financial Instruments Trading Act, or the requirements
stated  
in the listing agreements.                                           
          

Diamyd Medical AB (publ.)                                        
              
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8
6610026, Fax: +46 8 
661 63 68                                                
                      
E-mail: info@diamyd.com. VAT no: SE556530-142001.      
                        
(www.omxnordicexchange.com ticker: DIAM B;
www.otcqx.com ticker: DMYDY